Shomerosh

Company Overview

Snapshot

Founded in September 2016, Shomerosh operates with 1–10 employees and has raised $200K across one funding round. The company developed an app for detecting preclinical Alzheimer's disease, a technology that was recognized in September 2016 for its potential in early-stage mild cognitive impairment and Alzheimer's identification.

Business overview

Shomerosh, also known as Clara Mind, is a Health Tech & Life Sciences company focused on digital healthcare and medical diagnostics. The company develops a free, noninvasive, and user-friendly mobile application designed to detect Alzheimer's disease at its preclinical stage. Utilizing artificial intelligence and machine learning, its predictive model is based on a novel personalized cognitive task that can be completed remotely, aiming to identify early stages of the disease when neural pathology may still be reversible. Shomerosh serves both B2B and B2C markets, targeting healthcare providers, pharma companies, and patients within the neurology and aging population segments.

Company Intelligence Q&A

What is Shomerosh's primary focus?

Shomerosh focuses on developing a noninvasive, user-friendly mobile application for the early detection of preclinical Alzheimer's disease. The app utilizes a personalized cognitive task to identify the disease at its very early stages.

When was Shomerosh founded?

Shomerosh was founded in September 2016.

What is the status of Shomerosh?

Shomerosh is currently non-active, having ceased to operate in August 2024.

What technology does Shomerosh utilize?

Shomerosh's predictive model is based on artificial intelligence and machine learning, applied to a novel personalized cognitive task for early detection of Alzheimer's disease.

What was a key technological recognition for Shomerosh?

In September 2016, Shomerosh was recognized for its app that identifies early-stage mild cognitive impairment and Alzheimer's, highlighting its medical technology and early-detection capabilities.